TCGA-AR-A2LJ-01A-12R-A19W-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 88
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.430
- COAGULATION+0.410
- MYOGENESIS+0.410
- KRAS_SIGNALING_DN+0.330
- TNFA_SIGNALING_VIA_NFKB+0.320
- IL6_JAK_STAT3_SIGNALING+0.310
- ESTROGEN_RESPONSE_LATE+0.300
- PANCREAS_BETA_CELLS+0.300
- INFLAMMATORY_RESPONSE+0.290
- KRAS_SIGNALING_UP+0.290
Top 10 suppressed
- PROTEIN_SECRETION-0.570
- E2F_TARGETS-0.520
- G2M_CHECKPOINT-0.490
- MITOTIC_SPINDLE-0.440
- UNFOLDED_PROTEIN_RESPONSE-0.430
- ANDROGEN_RESPONSE-0.400
- MYC_TARGETS_V1-0.380
- MTORC1_SIGNALING-0.340
- MYC_TARGETS_V2-0.220
- TGF_BETA_SIGNALING-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OL-A66L-01A-12R-A31O-07 | — | B | 0.922 |
| 2 | SJEPD035_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.915 |
| 3 | TCGA-Z7-A8R5-01A-42R-A41B-07 | — | B | 0.911 |
| 4 | TCGA-FD-A43S-01A-21R-A23W-07 | — | — | 0.909 |
| 5 | TCGA-AC-A3BB-01A-21R-A19W-07 | — | A | 0.906 |
| 6 | TCGA-BH-A42U-01A-12R-A24H-07 | — | B | 0.906 |
| 7 | SRR1359171 | GTEX | — | 0.905 |
| 8 | SRR1491293 | GTEX | — | 0.905 |
| 9 | 22e9b9d1-ac71-43f5-8606-f9f53c6ecc08 | — | — | 0.884 |
| 10 | 9075936e-cc58-4740-abf4-1c733abb3d9f | — | — | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.430 | Idelalisib | — uncovered |
| COAGULATION | 0.410 | Binimetinib | — uncovered |
| MYOGENESIS | 0.410 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.330 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.320 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.310 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.300 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.290 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.290 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.290 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.280 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.250 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.250 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.240 | Inavolisib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.240 | Inavolisib | — uncovered |
| HYPOXIA | 0.220 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.210 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |